

RESERVE BANK OF NEW ZEALAND

STATEMENT OF ASSETS AND LIABILITIES OF THE RESERVE BANK OF NEW ZEALAND AS AT THE CLOSE OF BUSINESS ON WEDNESDAY, 20 NOVEMBER 1985

<i>Liabilities</i>	\$(000)	<i>Assets</i>	\$(000)
Overseas liabilities—		Overseas assets—	
Denominated in overseas currencies—		Denominated in overseas currencies—	
(a) Short term	224,954	(a) Short term	1,370,024
(b) Long term	1,153,634	(b) Long term	12,533
Denominated in New Zealand currency—		(c) Holdings of I.M.F. special drawing rights	15,795
(a) Short term	50,371	Denominated in New Zealand currency—	
(b) Long term	(a) Short term	2,792
	1,428,959	(b) Long term	699
Allocation of special drawing rights by I.M.F.	262,876	Gold
Deposits—		Advances and discounts—	
(a) State:		(a) State:	
Public account	1,488,196	Public account
Other	210,746	Other	1,208,150
(b) Marketing organisations	162,803	(b) Marketing organisations	9,709
(c) Stabilisation accounts	83,786	(c) Stabilisation accounts	495,558
(d) Trading banks	124,947	(d) Trading banks:	
(e) Other	19,718	Compensatory deposits
	2,090,196	Other	5,127
Notes in circulation	721,345	(e) Other	396
Other liabilities	201,118		1,718,940
Reserves—		Term Loans—	
(a) General reserve	100,000	Marketing organisations	800,000
(b) Other reserves	71,956	Investments in New Zealand—	
(c) Profit and loss appropriation account	(a) New Zealand Government securities	781,801
	171,956	(b) Other	11,870
	\$4,876,450	Other assets	793,671
			161,996
			\$4,876,450

G. K. FROGGATT, Chief Manager, Corporate Services.

Consent to the Distribution of New Medicines

PURSUANT to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

SCHEDULE

Name and Strength	Form	Name and Address of Manufacturer	Proprietary Name (if any)
Diflunisal BP 250 mg	Tablet	Pacific Pharmaceuticals Ltd., New Zealand	Ansal '250'
Isosorbide Dinitrate BP 10 mg & 30 mg	Tablet	Pacific Pharmaceuticals Ltd., New Zealand	Coronex '10' & '30'
Magnesium Sulphate 49.3% w/v	Injection (ampoule)	David Bull Laboratories Pty Ltd., Australia	-
Indomethacin BP 100 mg	Suppository	Glaxo Operations Ltd., England	-
Atropine Sulphate BP 400 mcg, 600 mcg & 1.2 mg in each ml	Injection (ampoules)	David Bull Laboratories Pty Ltd., Australia	-
Sodium Bicarbonate 8.4% w/v	Injection (ampoule)	David Bull Laboratories Pty Ltd., Australia	-
Edrophonium Chloride USP 10 mg in each ml	Injection (ampoule)	Taylor Pharmal Co., U.S.A.	Enlon
Glipizide 5 mg	Tablet	Farmitalia Carlo Erba, Italy	Minidiab
Tolciclate 1% w/v	Lotion	Farmitalia Carlo Erba, Italy	Tolmicen
Tolciclate 1% w/w	Cream	Farmitalia Carlo Erba, Italy	Tolmicen
Tolciclate 0.5% w/w	Powder	Farmitalia Carlo Erba, Italy	Tolmicen
(Disodium Edetate) 0.10% w/w	Solution	Alcon Laboratories Ltd., Canada	Soaclens
(Thiomersal) 0.004% w/w with surface-active agent			

Dated this 16th day of November 1985.

MICHAEL BASSETT, Minister of Health.